Linked Life Data

18787388

Source:http://linkedlifedata.com/resource/pubmed/id/18787388

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
2008-9-12
pubmed:abstractText
Hypercholesterolemia and Type 2 diabetes are well-recognized risk factors for cardiovascular disease, promoted by a condition of subclinical inflammation and a hypercoagulable state. Soluble CD40 ligand (sCD40L), a marker of vascular inflammation, seems to predict vascular damage in patients with Type 2 diabetes. Beside the lipid-lowering effect, statins seem to slow the progression of atherosclerosis through a series of anti-inflammatory effects, including a reduction of sCD40L levels. This study compared the effect of a short-term (12 weeks) treatment with rosuvastatin or simvastatin on some markers of inflammation in 36 patients with Type 2 diabetes and moderate hypercholesterolemia. As expected, both drugs significantly modified lipid profile; moreover, rosuvastatin and simvastatin were both able to significantly reduce albumin excretion rate in these patients, without affecting urinary N-acetyl-beta-D-glucosaminidase. Serum homocysteine was not influenced by the treatment, as interleukin-6 levels, while C reactive protein diminished; moreover, rosuvastatin, but not simvastatin, was able to significantly reduce sCD40L. The only clinical parameter related with the variations in sCD40L was systolic blood pressure. In hypercholesterolemic Type 2 diabetic patients, sCD40L, a factor playing a pivotal role in the pathogenesis of atherosclerosis and associated with more rupture-prone lesions, is reduced by short-term treatment with rosuvastatin.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
1720-8386
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
31
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
660-5
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Effect of statins on soluble CD40 ligand in hypercholesterolemic Type 2 diabetic patients.
pubmed:affiliation
Department of Internal Medicine, University of Pisa, I-56100 Pisa, Italy.
pubmed:publicationType
Journal Article, Clinical Trial